TY - JOUR
T1 - INTRAVITREAL BEVACIZUMAB in the MANAGEMENT of BREAST CANCER IRIS METASTASIS
AU - Seidman, Carly J.
AU - Finger, Paul T.
AU - Silverman, Joshua S.
AU - Oratz, Ruth
N1 - Publisher Copyright:
© Ophthalmic Communication Society, Inc.
PY - 2017
Y1 - 2017
N2 - Purpose: To report a case of neovascular and angle closure glaucoma secondary to breast cancer metastatic to the iris that was successfully treated with injections of intravitreal bevacizumab (Avastin) 1.25 mg/0.05 mL. Methods: Case report. Patients: A 47-year-old woman with metastatic breast cancer presented to The New York Eye Cancer Center with left ocular pain, photosensitivity, vision loss, and multiple iris nodules. Her intraocular pressure was uncontrolled. Gonioscopy revealed neovascularization of the iris and angle; no choroidal neovascularization was noted. Ultrasound biomicroscopy demonstrated tumor invasion of iris stroma with marked anterior uveal thickening and narrowed angles. Results: Three monthly injections of intravitreal bevacizumab resulted in nearly complete resolution of iris neovascularization, reduction of intraocular pressure, and control of tumor (although a small amount of residual tumor remained). Conclusion: Intravitreal anti-vascular endothelial growth factor therapy for breast cancer metastatic to the iris with secondary neovascular glaucoma provided good local control for a limited follow-up period, because the patient died because of systemic complications of her disease.
AB - Purpose: To report a case of neovascular and angle closure glaucoma secondary to breast cancer metastatic to the iris that was successfully treated with injections of intravitreal bevacizumab (Avastin) 1.25 mg/0.05 mL. Methods: Case report. Patients: A 47-year-old woman with metastatic breast cancer presented to The New York Eye Cancer Center with left ocular pain, photosensitivity, vision loss, and multiple iris nodules. Her intraocular pressure was uncontrolled. Gonioscopy revealed neovascularization of the iris and angle; no choroidal neovascularization was noted. Ultrasound biomicroscopy demonstrated tumor invasion of iris stroma with marked anterior uveal thickening and narrowed angles. Results: Three monthly injections of intravitreal bevacizumab resulted in nearly complete resolution of iris neovascularization, reduction of intraocular pressure, and control of tumor (although a small amount of residual tumor remained). Conclusion: Intravitreal anti-vascular endothelial growth factor therapy for breast cancer metastatic to the iris with secondary neovascular glaucoma provided good local control for a limited follow-up period, because the patient died because of systemic complications of her disease.
KW - angle closure glaucoma
KW - breast cancer
KW - intravitreal bevacizumab
KW - iris metastasis
KW - neovascular glaucoma
KW - ultrasound biomicroscopy
UR - http://www.scopus.com/inward/record.url?scp=85009754284&partnerID=8YFLogxK
U2 - 10.1097/ICB.0000000000000285
DO - 10.1097/ICB.0000000000000285
M3 - Article
C2 - 26862924
AN - SCOPUS:85009754284
SN - 1935-1089
VL - 11
SP - 47
EP - 50
JO - Retinal Cases and Brief Reports
JF - Retinal Cases and Brief Reports
IS - 1
ER -